Pipeline Insight: Neuropathic Pain - Emerging drugs fail to capitalize in lucrative market

Questions: Discounts, Updates etc.

Price: $11,400.00

Publication Date: 2007-09-26

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

The neuropathic pain market is forecast to double from 2006 to reach over $7 billion by 2016. At this time, the current late-stage neuropathic pain pipeline is forecast to take only 18% of the total market share, highlighting an opportunity for better pipeline drugs that demonstrate improved pain management. The most promising and closest pipeline drug to market is UCB's Vimpat (lacosamide).


Scope

  • Analysis of patient potential, unmet needs and clinical trial design in neuropathic pain
  • Overview of drugs in late- and early-stage clinical development; with analysis of key companies involved in the market
  • Detailed profiles of key compounds in development for use in neuropathic pain, with indication-specific drug sales forecasts to 2016
  • Discussion of Pfizer, Eli Lilly and UCB's market strategies and insight from key opinion leaders


    • Report Highlights
    UCB's increasing CNS portfolio is further bolstered by the imminent arrival of Vimpat on the market. CNS is a key area of investigation for UCB, constituting 39% of their sales in 2006. UCB has further expanded its reach by trialling this anticonvulsant not just for epilepsy but also for neuropathic pain, fibromyalgia, migraine and osteoarthritis.

    NeurogesX's Transacin (capsaicin) treatment is set to cause a stir in the topical market, currently dominated by Endo's Lidoderm (lidocaine 5% patch). The advantageous 3 monthly dosing regimen coupled with a strong efficacy and safety profile, will see Transacin draw favorable returns in its niche market.

    Pfizer will continue to be a major contender in neuropathic pain, with the current market leader Lyrica predicted to be an even greater commercial success than its predecessor Neurontin (gabapentin). Pfizer's branded drugs are forecast to capture a substantial 41% of the neuropathic pain market share in 2016.


    Reasons to Purchase

  • Understand unmet needs in the neuropathic pain market based on key opinion leader insight
  • Benchmark key late-stage neuropathic pain compounds against current market leaders
  • Assess the global (US, Japan, five major EU) sales forecasts of key late-stage pipeline drugs; and examine their clinical and commercial potential

    • Table of Contents

    Other users found this report page using the following search terms: neuropathic pain phn dnp pain neuropathic pipeline drugs drug market vimpat gabapentin sales enacarbil

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.


    Refund and Cancellation Policy: The descriptions of the products and services sold on LeadDiscovery.co.uk are as complete and accurate as possible, and customers are encouraged to read all available information about a product before placing an order. Due to the nature of the information being sold, orders for reports cannot be canceled.